Loading... Please wait.
Company profile
Hyloris Pharmaceuticals SA is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris Pharmaceuticals SA currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established.
Source:
Cofisem
-
Last Update:
21 Mar 2025
Key Executives
| Chief Executive Officer | Stijn Van Rompay | ||||
| Chief Financial Officer | Christophe Maréchal | ||||
| Chief Operating Officer | Dietmar Aichhorn | ||||
| Chief Business Development Officer | Thomas Jacobsen | ||||
| Source: Cofisem - Last Update: 21 Mar 2025 | |||||
Key figures
| Millenium | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 8.458 | 2.087 | 900 | 3.096 | 175 |
| Income from ordinary activities | 10.043 | 4.214 | 2.387 | 3.096 | 175 |
| Operating income | -7.129 | -15.993 | -11.638 | -10.541 | -7.025 |
| Cost of financial indebtedness net | -787 | -817 | 152 | 525 | 830 |
| Equity-accounted companies contribution to income | 0 | ||||
| Net profit from discontinued activities | |||||
| Net income | -6.342 | -15.380 | -11.906 | -11.579 | -7.145 |
| Net income (Group share) | -6.342 | -15.380 | -11.906 | -11.579 | -7.145 |
| Fiscal year end | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
| Source: Cofisem - Last Update: 21 Mar 2025 | |||||
Shareholder information
Address
Hyloris Pharmaceuticals SA
Boulevard Patience et Beaujonc 3/1
BE-4000
Liège
Belgium
Phone number:
+32 (0)4 346 02 07
Source:
Cofisem
-
Last Update:
21 Mar 2025
Contact
Christophe Maréchal
Source: Hyloris Pharmaceuticals SA - Last Update: 21 Mar 2025